Form 4: Relay Therapeutics CEO Sells Shares Under Pre-Arranged Trading Plan

Relay Therapeutics CEO, Sanjiv Patel, sold 375,000 shares of common stock through a family trust over three days, according to a recent SEC filing.

Summary

• Sanjiv Patel, the President and CEO of Relay Therapeutics, sold a total of 375,000 shares of common stock through the Patel Family Irrevocable Trust of 2019.
• The sales occurred over three days: 125,000 shares on January 21, 2025, at a weighted average price of $4.52, 125,000 shares on January 22, 2025, at a weighted average price of $4.80, and 125,000 shares on January 23, 2025, at a weighted average price of $4.78.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted by the trust on August 7, 2024.
• Following these sales, the Patel Family Irrevocable Trust of 2019 holds 199,548 shares.
• Mr. Patel also has 766,130 shares directly and 687,355 shares held by the SSP Irrevocable Trust of 2020.

Sentiment

Score: 5

Explanation: The document is neutral as it reports a routine stock sale under a pre-arranged plan. There is no indication of positive or negative sentiment from the document itself.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, potentially impacting investor confidence.
• The sales, while under a pre-arranged plan, could be interpreted as a lack of confidence in the company's future prospects by some investors.

Management Comments

• The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

Executive stock sales are a common occurrence, especially under pre-arranged trading plans, and are often a part of executive compensation and personal financial planning. The market typically reacts to these sales based on the volume and the context of the sales.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a standard practice for executives to sell shares without being accused of insider trading.
• The volume of shares sold is not unusual for a CEO of a company of this size, but the market reaction will depend on the overall sentiment towards the company.

Stakeholder Impact

• Shareholders may react to the news of the CEO's stock sales, although the pre-arranged nature of the sales may mitigate any negative impact.
• The impact on other stakeholders is likely to be minimal as this is a routine transaction.

Key Dates

Keywords

Relay Therapeutics, Sanjiv Patel, stock sale, insider trading, Rule 10b5-1, executive compensation, RLAY